TRAX

First Tracks Biotherapeutics

NASDAQ: TRAX · HEALTHCARE · BIOTECHNOLOGY

$47.78

+14.12% today

Updated 2026-07-30

Market cap

$1.29B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.76

Dividend yield

—

52W range

$11 – $43

Volume

0.8M

Market cap

$1.29B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.76

Dividend yield

—

52W range

$11 – $43

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$42.88

-10.26%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-32.58M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	TTM
Revenue	$0.00	$0.00	—	$0.00
Net income	$-106.15M	$-163.71M	$-166.09M	$-50.48M
EPS	—	—	—	$-4.76
Free cash flow	$-93.81M	$-126.16M	$-143.01M	$-32.58M
Profit margin	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TRAX	$1.29B	24	4.3	3.0	5.0	5.5	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

First Tracks Biotherapeutics trades at $47.78. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score.

Frequently asked questions

What is First Tracks Biotherapeutics's stock price?

First Tracks Biotherapeutics (TRAX) trades at $47.78.

Is First Tracks Biotherapeutics overvalued?

First Tracks Biotherapeutics carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of First Tracks Biotherapeutics (TRAX)?

The 12-month analyst consensus target is $42.88, about 10.3% below the current $47.78. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-64.51%

Beta—

50D MA$20.39

200D MA$20.68

Shares out0.03B

Float0.03B

Short ratio—

Avg volume0.8M

Performance

1 week+7.27%

1 month+111.65%

3 months+116.88%

YTD—

1 year—

3 years—

5 years—

Compare

TRAX vs LLY →TRAX vs JNJ →TRAX vs ABBV →Stock screener →